End-to-End Advanced Therapy Solutions
Process Development & Manufacturing Innovation Manifesting the Promise of Advanced Therapies
As a leading global CDMO devoted to developing and manufacturing advanced therapies, Recipharm Advanced Bio specializes in xRNA therapies, viruses and viral vectors, microbial and live biotherapeutic products, and recombinant protein vaccines.
With operations in the United States and Europe, we have curated technologies, capabilities, and capacity to offer end-to-end solutions that streamline your development programs and avoid costly and time-intensive technology transfer. We are a leading CDMO supporting the work of xRNA therapy innovators by leveraging our integrated plasmid DNA, xRNA, and lipid nanoparticle (LNP) formulation capabilities.
Expertise & Capabilities Supporting the Diverse Advanced Therapy Pipeline
Recipharm Advanced Bio does not back down from a challenge and is deeply committed to advancing wide-ranging advanced therapeutic modalities.
Recipharm Advanced Bio’s Origins
Recipharm Advanced Bio was formed in 2022 out of the merger of three highly successful specialty CDMO entities, resulting in the assembly of decades of advanced therapies expertise.
Recipharm Advanced Bio is a global CDMO with centers of excellence dedicated to nucleic acids in the USA, virus and viral vector manufacturing in Germany, and recombinant proteins and live biotherapeutic products in Portugal. Backed by best-in-industry process development talent and deep expertise across xRNA, plasmids, viral vectors, and the microbiome, Recipharm Advanced Bio is advancing the next generation of therapeutics and building capabilities for the future of biomanufacturing.
Dedication to Transparent, Strong Relationships
Advancing together – tackling the challenges of promising yet complex therapeutics – requires relationships built on clear and honest communication. Recipharm Advanced Bio does not create ‘black boxes’ or withhold critical process details as privileged information. Rather, we foster trust and collaboration through highly transparent communication and continual engagement.
- Access to all documentation–batch records, SOPs, material specifications
- Our subject matter experts conduct technical planning and problem-solving directly with your team
- Site management interfaces with program leaders, providing functional oversight
- Our executive leadership engages and builds relationships to foster strategic and holistic support of your program
- Our business development and project management teams build consistency and clarity around the relationship for long-term success
Expertise from CDMO and Innovator Perspectives
Recipharm Advanced Bio’s expert scientific team has significant lived experience developing novel advanced therapies from both the innovator and advanced therapy CDMO perspectives. We channel this experience when navigating the development and manufacture of a complex new modality to provide the guidance and solutions needed to strengthen your program.
Flexibility Needed to Support Novel Therapeutic Innovations
Developing novel advanced therapies is often an unpredictable endeavor. Timelines can shift for many reasons, but Recipharm Advanced Bio’s capabilities and culture allow us to pivot rapidly to keep the program on track.
Innovation & Collaboration Are in Our DNA
Above all, we are committed to finding better and more efficient ways to develop and manufacture advanced therapeutics to improve patient accessibility worldwide. From an $82 million FDA grant and collaboration with MIT to create a continuous xRNA manufacturing platform to a Gates Foundation grant to improve access to RNA therapeutics in low- and middle-income countries to working with NewBiologix to improve yields for new AAV therapies, Recipharm Advanced Bio is driving ATMP innovation.
Our Team of Experts
Our scientific and leadership teams ensure our clients’ success and support ongoing manufacturing innovation, improving the quality and efficiency of ATMP manufacturing processes.
Aaron Cowley
Chief Scientific Officer, USA
Kai Lipinski
Chief Scientific Officer, Germany
Jing Zhu
VP, Head of Process Development
Christin Gasch
Head of Process Development
Jovanka Bogojeski
Senior Director of Scale Up & Tech Transfer, mRNA
Aula Al Muslim
Associate Director
Frank Zhang
Associate Director
Enshi Liu
Principal Scientist, Process Development
Bárbara Cunha
Tech Transfer and Project Management Director
Our Facilities
Our scientific and leadership teams ensure our clients’ success and support ongoing manufacturing innovation, improving the quality and efficiency of ATMP manufacturing processes.
Watertown, Massachussetts, USA
- Established
- 2019 (Arranta Bio)
- Size
- 80,000 ft2
- Employees
- 150+
Key Attributes
- Meets BSL-2 requirements
- Multi-product facility
- Pre-clinical through commercial production
- Development and manufacturing services:
- xRNA and DNA
- Plasmid DNA
- Lipid nanoparticles
- Microbiome & live biotherapeutic products (LBP)
- Additional services:
- Bacterial cell banking
- Sterile fill-finish
Facility Highlights
- xRNA Center of Excellence
- xRNA continuous manufacturing
- Process Analytical Technologies Center of Excellence
- Live biotherapeutic product specialists
Oeiras, Portugal
- Established
- 2006 expansion opened in 2024 (IBET)
- Size
- 17,000 ft2
- Employees
- 100+
Key Attributes
- Meets BSL-2 requirements
- Multi-product facility
- Pre-clinical through commercial production
- Development and manufacturing services:
- xRNA and DNA
- Plasmid DNA
- Lipid nanoparticles
- Virus & viral vectors
- Recombinant proteins
- Microbiome & live biotherapeutic products (LBP)
- Additional services:
- Viral & bacterial cell banking
- Sterile fill-finish
Facility Highlights
- EU GMP certificate, FDA commercial license
- Cell culture & downstream purification expertise
- Recombinant proteins for malaria vaccines
- Commercial experience for several novel therapeutics
Cuxhaven, Germany
- Established
- 2002 (Bioprotect Research)
- Size
- 110,000 ft2 (expansion in progress)
- Employees
- 100+
Key Attributes
- Meets BSL-2 requirements
- Multi-product facility
- Pre-clinical through commercial production
- Development and manufacturing services:
- Virus & viral vectors
- Oncolytic virus
- Additional services:
- Viral & bacterial cell banking
- Sterile fill-finish
Facility Highlights
- Viral Vector Center of Excellence
- AAV platform development
- Expansion, preparing the site for commercial manufacturing
- Pre-Approval Inspection by FDA (H1 2024)
- German Health Inspectorate GAA (H2 2025)
- GMP Oncolytic virus development & manufacturing
- Fully automated and manual fill-finish
Wasserburg, Germany
- Established
- 2010 (acquired)
- Size
- 344,450 ft2
- Employees
- ~400
Key Attributes
- Leading sterile manufacturing facility located south of Munich, Germany
- Lyophilization Center of Excellence
- Fills in vials with highly automated, state-of-the-art equipment
- Small run, aseptic liquid filling into vials or ampoules
- Ranging vial and ampoule sizes
- Flexible batch sizes
- Multi-product facility
Facility Highlights
- Approved by the local German Government (EU-GMP), Russia, US FDA, KFDA, TGA, GCC-DR, HPB Health Canada, Japan, ANVISA, and the Drug and Medical Device Institute of Turkey
- ISO 14001, ISO 45001, ISO 50001 certified
Advancing Your Program Together
Your program isn’t just another project—it’s a breakthrough in the making. At Recipharm Advanced Bio, we bring deep scientific expertise, innovative thinking, and a problem-solving mindset to every partnership. Whether scaling a complex process, navigating regulatory pathways, or optimizing for commercial success, we’re here to collaborate, adapt, and deliver with excellence.
Let’s push the boundaries of possibility together and bring transformative therapies to patients faster.